Core Points - A shareholder class action lawsuit has been filed against Lifecore Biomedical, Inc. alleging that the company made materially false and misleading statements regarding its business and operations [3] - The lawsuit claims that Lifecore had deficient internal controls over financial reporting, leading to inaccurate financial statements that would need to be restated [3] - It is alleged that Lifecore's remediation efforts regarding these deficiencies were ineffective, impairing the company's ability to file periodic reports with the SEC in compliance with NASDAQ requirements [3] - The lawsuit asserts that Lifecore's financial position and prospects were materially overstated as a result of these issues [3] - The deadline for shareholders to request to be appointed as lead plaintiff in the case is September 27, 2024 [4]

Core Viewpoint - A securities class action lawsuit has been filed against Lifecore Biomedical, Inc. for allegedly making materially false and misleading statements regarding its financial reporting and internal controls [2][4]. Group 1: Allegations of Misconduct - The lawsuit claims that Lifecore failed to disclose deficiencies in its internal controls over financial reporting [1][4]. - It is alleged that Lifecore issued inaccurate financial statements that would require restatement due to these deficiencies [1][4]. - The company's remediation efforts regarding these internal control deficiencies were deemed ineffective [1][4]. - Lifecore's inability to file periodic reports with the SEC in a timely manner is also highlighted as a significant issue [1][4]. - The lawsuit asserts that the company's financial position and prospects were materially overstated as a result of these issues [1][4]. Group 2: Impact on Stock Price - Following the revelation of these issues, Lifecore's stock price dropped by $2.18 per share, representing a decline of 30.32%, closing at $5.01 per share on March 20, 2024 [6]. Group 3: Class Action Details - The class action lawsuit covers all individuals or entities that purchased Lifecore securities between October 7, 2020, and March 19, 2024 [2]. - Investors are encouraged to contact the law firm representing the class action before the lead plaintiff motion deadline on September 27, 2024 [5].

If you suffered substantial losses and wish to serve as lead plaintiff of the Lifecore Biomedical class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449- 4900 or via e-mail at info@rgrdlaw.com. The Lifecore Biomedical class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Lifecore Biomedical maintained defi ...

About Lifecore Biomedical The RSU award will vest and be settled as to 25,000 shares of the RSU on May 20, 2024 and as to 100,000 shares of the RSU on each of the first five anniversaries of May 20, 2024 and is governed by a Restricted Stock Unit Award Agreement and the Inducement Plan. The PSU award will vest, if at all, based upon the Performance Price achievement within the five year performance period as compared to a range of ten prices from $7.50 per share to $35.00 per share. The Performance Price is ...

On May 10, 2024, the Company also entered into the Seventh Amendment to the ABL Loan Agreement with its ABL lender to execute a "first-in, last-out" tranche of revolving loans under the ABL Loan Agreement (the "FILO Amendment"). While not increasing the overall revolver commitment of $40 million, the FILO Amendment provides for up to approximately $2.5 million of incremental revolving loan capacity to the Company, subject to a variable cap, without changing the collateral. In connection with the FILO Amendm ...

CHASKA, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), announced certain incremental liquidity measures and housekeeping matters related to divested businesses through a series of 8-K filings over the past week. James G. Hall, President and Chief Executive Officer of Lifecore, commented, "We believe these incremental liquidity improvements will provide Lifecore wi ...

2 Investor Present April 2024 Important Information Regarding Forward-Looking St This presentation contains forward-looking statements regarding future events and the future results of Lifecore Biom‹ "Company") that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and ot the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as "anticipate", "estimate", "expect", "pro "believe", "may", "might", "will", "should", "can have", "likely" an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended May 28, 2023, or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition period from _________ to _________. Commission file number: 000-27446 LIFECORE BIOMEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 94-3025618 ( ...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q4 2023 Results Conference Call August 31, 2023 8:30 AM ET Company Participants Jeff Sonnek - IR-ICR Jim Hall - President, CEO John Morberg - CFO Operator Good morning, and thank you for joining Lifecore's Fiscal 2023 Fourth Quarter Earnings Call. [Operator Instructions]. Now I'd like to turn the call over to Jeff Sonnek, Investor Relations at ICR. Jeff Sonnek Good morning, and thank you for joining us today to discuss Lifecore Biomedical's Fourth Quarter and Full Yea ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Quarter Ended February 26, 2023, or For the Transition period for _________ to _________. Commission file number: 000-27446 LIFECORE BIOMEDICAL, INC. Delaware 94-3025618 (State or other jurisdiction of incorporation ...